ArticleEsophagus : official journal of the Japan Esophageal Society2026
The risk of distant organ metastasis and survival analysis in esophageal cancer with different histological subtypes.
Article in Esophagus : official journal of the Japan Esophageal Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
backgroundThe impact of histological subtypes on distant organ metastasis remains insufficiently elucidated in patients with esophageal cancer. This study aims to discuss the risk of distant organ metastasis and its effect on survival in esophageal cancer patients.
methodsPatients with esophageal cancer, including adenocarcinoma (AC), squamous cell carcinoma (SCC), adenosquamous carcinoma (ASC), neuroendocrine carcinoma (NECS), and signet-ring cell carcinoma (SRCC), were selected from the SEER database. Logistic regression was employed to assess the risk of esophageal cancer metastasis to various organs, while Cox proportional hazards regression, Kaplan-Meier curves and the Log-rank test was used for survival analysis.
resultsCompared to AC, patients with SCC exhibit a lower risk of developing bone, brain, and liver metastases, SRCC have a reduced risk of brain, liver, and lung metastases, and NECS are more likely to develop liver metastasis. Among patients with bone and lung metastases, those with SRCC or SCC experience poorer survival. SRCC is associated with worse prognosis in cases of brain metastasis, while SCC predicts inferior outcomes in liver metastasis. Among patients with AC or SCC, those with lung metastasis demonstrate better survival compared to those with bone or liver metastases.
conclusionIn patients with esophageal cancer, organ-specific metastasis and post-metastatic survival are histology-dependent. Among the two most common histological types, AC and SCC, SCC shows a lower risk of distant metastasis. However, once metastasis occurs, patients with SCC have poorer survival compared to those with AC.
Indexed as
Identifiers
42265435What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.